

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE
03 AUG 21 11 2: 52

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Genzyme Corporation</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>1020 Nineteenth Street, NW, Suite 550, Washington, DC 20036</u>			
3. Principal Place of Business (if different from line 2) City: <u>Cambridge</u> State/Zip (or Country) <u>MA 02139</u>			
4. Contact Name <u>Mary McGrane</u>	Telephone <u>(202) 296-3280</u>	E-mail (optional)	5. Senate ID # <u>16054-12</u>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # <u>30257000</u>

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more ⇒ \$ _____
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more ⇒ \$660,000.00
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate expected accounting method. See instructions for description of options.

Method A. Reporting amounts using LDA definitions

Method B. Reporting amounts under section 6033(b) Internal Revenue Code

Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature _____

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

LD-2 (REV. 6/98)

PAGE

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

a) Medicare Prescription Drug Benefit:

- S. 1 – “Prescription Drug and Medicare Improvement Act of 2003”
- S. 7 – “Prescription Drug Benefit and Cost Containment Act of 2003”
- S. 778 – “Medicare Rx Drug Discount and Security Act of 2003”
- S. 891 – “Prescription Drug Equity for Seniors Act of 2003”
- S. 892 – “Prescription Drug Fairness for Seniors Act of 2003”
- H.R. 1 – “Medicare Prescription Drug and Modernization Act of 2003”
- H.R. 513 – “Medicare Rx Drug Discount Act of 2003
- H.R. 1045 – “Medicare Outpatient Prescription Drug Coverage Act of 2003”
- H.R. 1199 – “Medicare Rx Drug Benefit and Discount Act of 2003”
- H.R. 1400 – “Prescription Drug Fairness for Seniors Act of 2003”
- H.R. 1568 – “Medicare Rx Now Act of 2003”
- H.R. 2473 – “Medicare Prescription Drug and Modernization Act of 2003”
- H.R. 2578 – “Medicare for the 21st Century Act”

b) Support modification of Medicare hospital prospective payment system for hospital outpatient departments:

- H.R. 26 – “Medicare Payment Restoration and Benefits Improvement Act of 2003”
- H.R. 1032 – “Beneficiary Access to Care Act of 2003”
- H.R. 2700 – “Medicare Patient Access to Drugs for Rare Diseases Act of 2003”

c) Medicare payment system for physician-administered drugs

- H.R. 194 – “Medicare Market Acquisition Drug Price Act of 2003”

d) Medicare coverage for new medical technology

- S. 823 - “Medicare Innovation Responsiveness Act of 2003”
- H.R. 569 – “Medicare Patient Access to Preventive and Diagnostic Test Act”
- H.R. 941 – “Medicare Innovation Responsiveness Act of 2003”

e) Support Medicare coverage of oral phosphate-binding drugs

17. House (s) of Congress and Federal agencies contacted

Ch

- a) United States Senate
United States House of Representatives
Executive Office of the President
Department of Health and Human Services
- b) United States House of Representatives
United States Senate
Department of Health and Human Services
General Accounting Office

- c) United States Senate
United States House of Representatives
Department of Health and Human Services
- d) United States Senate
United States House of Representatives
- e) United States Senate
United States House of Representative.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature

Date 5 August 2003

Signature _____ Date 5 August 2009

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

Form LD-2 (Rev.6/98)

Page 4

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

a) Pediatric research for drugs and biologics

S. 650 – “Pediatric Research Equity Act of 2003”
H.R. 2857 - “Pediatric Research Equity Act of 2003”

b) Rare diseases and orphan drug development

H.R. 2700 – “Medicare Patient Access to Drugs for Rare Diseases Act of 2003”

c) Federal oversight and regulation of gene therapy research and protection of human research subjects

17. House (s) of Congress and Federal agencies contacted

Check if None

a) United States Senate
United States House of Representatives

b) United States Senate
United States House of Representatives


c) United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 5 August 2003

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

Form LD-2 (Rev.6/98)

Page 6

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Oppose creation of a system to approve generic biologics:

S. 54 – “Greater Access to Affordable Pharmaceuticals Act of 2003”

S. 946 – “Drug Competition Act of 2003”

S. 1225 – “Greater Access to Affordable Pharmaceuticals Act”

H.R. 2491 – “Greater Access to Affordable Pharmaceuticals Act”

17. House (s) of Congress and Federal agencies contacted

Check if None

United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 5 August 2003

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the regi: engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** p information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Oppose importation of drugs from outside the United States

H.R. 616 – “Prescription Drug Affordability Act”

H.R. 2427 – “Pharmaceutical Market Access Act of 2003”

H.R. 2491 – “Greater Access to Affordable Pharmaceuticals Act”

H.R. 2497 – “Prescription Drug Parity for Americans Act”

H.R. 2629 – “New Aid for Trustworthy, Affordable Drugs Act (NAFTA Drugs Act)”

17. House (s) of Congress and Federal agencies contacted

Check if None

United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 5 August 2003

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

Registrant Name Genzyme Corporation (16054-12)

Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

- a) Support tax credits for purchase of outpatient prescription drugs
S. 951 – “Older Americans Prescription Drug Tax Relief Act”
- b) Support expansion of the orphan drug tax credit

H.R. 878 – “Armed Forces Tax Fairness Act of 2003”
H.R. 2931 – “Orphan Drug Tax Credit Act of 2003”

17. House (s) of Congress and Federal agencies contacted

Check if None

United States Senate
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 5 August 2003

